Why Neurocrine Biosciences Stock Is Back in Focus
Neurocrine Biosciences (NBIX) is drawing fresh attention after third quarter 2026 results showed revenue of US$1.12b, up from US$794.9m a year earlier, while quarterly net income held near US$206.5m.
At a share price of US$145.35, Neurocrine Biosciences has seen the 90 day share price return fall 12.47%, while a 5 year total shareholder return of 55.34% and the latest earnings release keep longer term momentum intact in investors’ minds.
Spot opportunities with a similar profile to Neurocrine Biosciences by scanning a hand picked 33 healthcare AI stocks that are also tying medical expertise to advanced therapeutic platforms.The recent pullback in Neurocrine Biosciences after strong year to date and multi-year returns presents a clear decision point for investors: lean into the current price, or wait and hope for a cheaper entry as the valuation case unfolds next.
Most Popular Narrative: 29.7% Undervalued
Neurocrine Biosciences is trading at $145.35 against a widely followed fair value view of about $206.81, which frames the recent pullback as a valuation gap rather than just a sentiment swing.
Expansion of Neurocrine Biosciences’ commercial portfolio beyond INGREZZA through the launch of CRENESSITY and the acquisition of VYKAT XR, which together supplied about 25% of Q2 2026 revenue off a roughly US$1b quarterly base, broadens revenue sources and can improve margin resilience as the company spreads infrastructure and R&D spending across three first in class endocrinology and neuropsychiatry franchises.
See why 50 investors see Neurocrine Biosciences as 30% undervalued.
Result: Fair Value of $206.81 (UNDERVALUED)
Still, the thesis around Neurocrine Biosciences can unravel quickly if INGREZZA faces steeper Medicare pricing pressure or if VYKAT XR safety concerns lead to tighter regulation.
Find out about the key risks to this Neurocrine Biosciences narrative.
Next Steps
Curious whether the optimism in this Neurocrine Biosciences story really holds up under your own scrutiny? Act quickly, review the data that matters to you, and then pressure test the upside case with the 4 key rewards.
Looking for more investment ideas beyond Neurocrine Biosciences?
Do not stop with Neurocrine Biosciences. Broaden your watchlist using focused stock ideas that match your risk comfort and return expectations, before the best setups move away.
- Hunt for potential mispricing by scanning a curated pool of quality companies that still look cheap on the numbers through the 34 high quality undervalued stocks.
- Prioritise stability and staying power by reviewing a list of solid balance sheet and fundamentals (24 results) that can handle tough conditions without constant refinancing worries.
- Get ahead of the crowd by searching the 19 high quality undiscovered gems where strong fundamentals have not yet attracted broad market attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com